ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I AgreeHow to configure browser
Accionistas
RigurosityOur clinical studies are rigurously analyzed 
EfficiencyWe optimize our own resources 
AgilityWe adopt agile decissions 
Marta BarrachinaCEO
Ramón ReñéCHIEF MEDICAL OFFICER
Jordi GascónCHIEF SCIENTIFIC OFFICER